Labiotech.eu

Screenshot 2016 10 21 at 12.29.43 PM e1477045913351

News and Trends 21 Oct 2016

New Partnership comes to the Rescue in Neurological Diseases

Developing effective treatments for neurological diseases is a big challenge in medicine. But here come UCB and Evotec with a new partnership that could help those suffering from epilepsy and Parkinson’s. UCB is a Biotech from Brussels that focuses on neurological and immune diseases. The company has multiple products on the market, including an antibody drug for arthritis and […]

October 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 10 20 at 6.49.20 PM e1476982237695

News and Trends 21 Oct 2016

It’s time to Modernize Anesthetics! Meet the PAIONeers

We travel from Finland back to the heart of Europe to visit the beautiful sights of Aachen. The citizens are starting to turn on the heat and get ready for its famous Christmas markets, while we visit our Biotech of the week, Paion. City: Aachen, Germany Founded: 2000 Employees: 35 Financial Data: €163M market cap + €10M in […]

October 21, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 21 Oct 2016

Mallorca’s not just for Holidays: Sanifit starts Phase II in a Rare Disease

Forget about Madrid and Barcelona, the island of Mallorca has one of the hottest Biotechs in Spain: Sanifit is targeting calciphylaxis, an orphan disease that affects the huge dialysis market. Sanifit received the highest financing round in Spain last year (and probably ever) with €36.6M in series C. With this money, the company is advancing its candidate SNF472 in […]

October 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Oct 2016

German Record-deal Antiviral drug Succeeds in Phase III

AiCuris’ Letermovir succeeds in Phase III after being licensed to MSD in a record €442.5M deal. It acts on a novel CMV target to treat bone marrow transplant infections. AiCuris is a spin-out company from Bayer, Germany’s biggest Pharma, that focuses on developing drugs for infectious diseases. The company licensed its candidate Letermovir (AIC246) to MSD (Merck & co.) in 2012, making it the […]

October 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Oct 2016

CRISPR Thx’ surprisingly low IPO… why are Investors Discouraged?

Troubled waters in the CRISPR field: CRISPR Therapeutics’ IPO hits an unexpectedly low price. It seems that the investors are starting to switch from hype to uncertainty, but why now? CRISPR Therapeutics has just announced the results of a surprisingly low IPO: €51M ($56M), way lower than its €80M target. Its competitors in the therapeutics CRISPR field, Editas […]

October 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Oct 2016

Planning a Clinical Trial? Here’s why Data Management matters

Data from therapy development, especially those involving cells, can quickly mushroom into an unmanageable pile in the lab — what happens when you move to the clinic? We sat down with Venn Life Sciences to discuss effective strategies in data management that might benefit companies looking to bring a therapy like Tregs to market. Cell […]

October 20, 2016 - 4 minutesmins - By External Contributor

News and Trends 19 Oct 2016

The ‘First and Only’ Metastatic Lung Cancer Immunotherapy is approved

Roche’s Genentech has received FDA approval for an immunotherapy targeting the highly sought-after PD-L1. The treatment may be able to outperform its competitors in lung cancer therapies. In May, Roche received approval for Tecentriq (atezolizumab) in bladder cancer. Now, the drug is expanding its indications to become the first and only cancer immunotherapy in the market to target […]

October 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Oct 2016

And the highest funding in Europe this year goes to… Antibody-Drug Conjugates!

AstraZeneca has contributed to ADC Therapeutics’ €96M fundraising, the biggest round so far in Europe this year. Will this huge investment pay out for the British-Swedish Big Pharma? ADC Therapeutics (ADCT) is a Swiss Biotech that develops antibody-drug conjugates (ADCs) for oncology applications. Its founder Auven Therapeutics and its partner AstraZeneca have participated in the biggest […]

October 19, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Oct 2016

This Technology Opens new Horizons for Protein Production

Based in Cologne, Germany, Cevec focuses on human cell-based expression system for production of biological therapies. We’ve already covered their breakthroughs for safer gene therapy and the potential of CAP-GT for expression of viral vectors. Besides CAP-GT, CEVEC has also developed a cell line that can produce complex glycosylated proteins. A good example of glycosylated protein is […]

October 19, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 18 Oct 2016

Shire’s leading Pancreatic Cancer drug is Back with a Bang

Pancreatic cancer is one of the nastiest kinds and most difficult to treat; the EMA has granted marketing authorization to Onivyde in the fight against it. Pancreatic cancer is the fourth-leading cause of death in Europe, and it represents a dramatically underserved need. Metastatic adenocarcinoma is almost always fatal, as it cannot be removed surgically […]

October 18, 2016 - 2 minutesmins - By Evelyn Warner

Screenshot 2016 10 18 at 5.42.27 PM e1476805403921

News and Trends 18 Oct 2016

This New Biotech wants to Regrow Neurons to cure Parkinson’s

Mavalon Therapeutics will develop a drug candidate for Parkinson’s that can stop the disease progression by activating the growth of dying neurons. Mavalon Therapeutics, born today in the UK, will be entirely dedicated to the development of a drug candidate to stop the progression of Parkinson’s. Domain Therapeutics has created this new company with a €9M investment […]

October 18, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Oct 2016

€4M Grant for a Cancer Vaccine that could Bench its Competitors

Hookipa just secured a huge grant from the Austrian government. The plan is to develop the strongest HPV vaccine ever and claim its place in the €2B head and neck cancer market. Hookipa, one of the hottest Biotechs in Vienna, develops vaccines based on a new class of viral vectors. Its platform has impressed the public sector and secured €4.16M from the Austrian […]

October 18, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

New Partnership comes to the Rescue in Neurological Diseases

It’s time to Modernize Anesthetics! Meet the PAIONeers

Mallorca’s not just for Holidays: Sanifit starts Phase II in a Rare Disease

German Record-deal Antiviral drug Succeeds in Phase III

CRISPR Thx’ surprisingly low IPO… why are Investors Discouraged?

Planning a Clinical Trial? Here’s why Data Management matters

The ‘First and Only’ Metastatic Lung Cancer Immunotherapy is approved

And the highest funding in Europe this year goes to… Antibody-Drug Conjugates!

This Technology Opens new Horizons for Protein Production

Shire’s leading Pancreatic Cancer drug is Back with a Bang

This New Biotech wants to Regrow Neurons to cure Parkinson’s

€4M Grant for a Cancer Vaccine that could Bench its Competitors

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!